BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalogirou EM, Tosios KI, Christopoulos PF. The Role of Macrophages in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:611115. [PMID: 33816242 DOI: 10.3389/fonc.2021.611115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Gorvel L, Olive D. Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation. Seminars in Immunology 2023;65:101671. [DOI: 10.1016/j.smim.2022.101671] [Reference Citation Analysis]
2 He Y, Yang D, Li Y, Xiang J, Wang L, Wang Y. Circular RNA-related CeRNA network and prognostic signature for patients with oral squamous cell carcinoma. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.949713] [Reference Citation Analysis]
3 Gaafar NM, Osman TA, Elsheikh M, Ahmed IA, Dongre H, Fromreide S, Suleiman AM, Johannessen AC, Nginamau ES, Costea D. Epithelial PD‐L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan. Clinical & Exp Dental Res 2022. [DOI: 10.1002/cre2.666] [Reference Citation Analysis]
4 Xue Y, Song X, Fan S, Deng R. The role of tumor-associated macrophages in oral squamous cell carcinoma. Front Physiol 2022;13:959747. [DOI: 10.3389/fphys.2022.959747] [Reference Citation Analysis]
5 Ansary TM, Hossain MR, Komine M, Ohtsuki M. Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges. IJMS 2022;23:8530. [DOI: 10.3390/ijms23158530] [Reference Citation Analysis]
6 Zhang L, Zhao S, Liu Y, Lv F, Geng X. Identification and validation of transcription factor-driven enhancers of genes related to lipid metabolism in metastatic oral squamous cell carcinomas. BMC Oral Health 2022;22. [DOI: 10.1186/s12903-022-02157-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen J, Zhou C, Liu Y. Establishing a Macrophage Phenotypic Switch-Associated Signature-Based Risk Model for Predicting the Prognoses of Lung Adenocarcinoma. Front Oncol 2021;11:771988. [PMID: 35284334 DOI: 10.3389/fonc.2021.771988] [Reference Citation Analysis]
8 Chiang I, Lee Y, Tan Z, Hsu F, Tu H. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomedicine & Pharmacotherapy 2022;147:112661. [DOI: 10.1016/j.biopha.2022.112661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Shetty SS, Padam KSR, Hunter KD, Kudva A, Radhakrishnan R. Biological implications of the immune factors in the tumour microenvironment of oral cancer. Arch Oral Biol 2021;133:105294. [PMID: 34735925 DOI: 10.1016/j.archoralbio.2021.105294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]